asthma
heterogen
chronic
inflammatori
famili
disord
airway
increas
preval
result
recurr
revers
bronchial
obstruct
expiratori
airflow
limit
diseas
aris
interact
environment
genet
factor
collabor
caus
increas
suscept
sever
mani
asthma
suscept
gene
link
immun
system
encod
enzym
like
metalloproteas
eg
serin
proteas
famili
serin
proteas
prolyl
oligopeptidas
capabl
process
peptid
bond
adjac
prolin
kind
cleavageresist
peptid
bond
present
mani
growth
factor
chemokin
cytokin
import
asthma
curious
two
serin
proteas
within
famili
encod
gene
locat
chromosom
appear
role
asthma
peptidas
aim
review
summar
current
knowledg
provid
structur
overview
numer
function
implic
versatil
enzym
could
diseas
especi
detect
secondari
effect
eg
viral
nasopharyng
type
ii
diabet
mellitu
patient
subset
certain
risk
develop
obesityrel
asthma
upon
inhibitori
therapi
asthma
heterogen
chronic
diseas
character
revers
expiratori
airflow
limit
bronchial
hyperrespons
mucou
cell
hyperplasia
higher
vasculatur
permeabl
airway
remodel
fibrosi
inflammatori
cell
infiltr
asthma
major
concern
million
peopl
worldwid
affect
increas
preval
high
econom
charg
frequent
sever
boy
age
year
preval
sever
asthma
rise
women
puberti
becom
even
preval
femal
five
case
display
highli
sever
treatmentrefractori
diseas
suffer
recurr
exacerb
threaten
patient
life
increas
healthcar
cost
complex
patholog
genet
environment
factor
caus
increas
suscept
sever
great
effort
made
discov
genet
base
mostli
genomewid
associ
studi
asthma
gwa
reveal
influenc
sever
gene
encod
protein
import
role
immun
system
hladq
hlag
tslp
pde
also
proteas
dipeptidyl
peptidas
asthma
prolyl
oligopeptidas
famili
proteas
dipeptidyl
peptidas
comment
proteas
involv
mani
physiolog
patholog
process
includ
chronic
respiratori
condit
like
asthma
amongst
proteas
prolinespecif
enzym
peptid
bond
adjac
prolin
present
growth
factor
chemokin
cytokin
resist
cleavag
enzym
includ
serin
proteas
serin
residu
catalyt
region
sequenc
consensu
glyxaaserxaagli
cover
differ
famili
subfamili
thu
famili
prolyl
oligopeptidas
includ
catalyt
triad
ser
asp
slightli
differ
sequenc
consensu
around
catalyt
ser
exampl
member
subfamili
ec
fibroblast
activ
proteinfapsepras
http
meropssangeracuk
present
sequenc
glytrpsertyrglygli
addit
two
member
dppx
glylysasptyrglygli
glylysglytyrglygli
possess
catalyt
serin
therefor
activ
curious
four
peptidas
fap
type
ii
membran
protein
releas
extracellular
medium
three
encod
gene
locat
chromosom
fap
two
appear
role
asthma
exampl
link
asthma
suscept
differ
popul
protein
well
primarili
locat
trachea
bronchi
airway
rat
part
proteas
major
member
famili
also
receptor
middl
east
respiratori
syndrom
coronaviru
merscov
new
coronaviru
caus
sever
lower
respiratori
tract
infect
could
lead
asthma
exacerb
found
elev
plasma
sampl
solubl
surfac
peripher
cell
adult
patient
allerg
asthma
differ
anim
model
suggest
role
peptidas
pathogenesi
diseas
structur
molecul
singlepass
type
ii
integr
membran
glycoprotein
kda
homodimer
form
biolog
activ
homodimer
take
place
golgi
apparatu
endoplasm
reticulum
monom
display
highli
conserv
short
six
amino
acid
cytoplasm
tail
nterminu
acid
hydrophob
transmembran
region
long
extracellular
domain
amino
acid
heavili
nglycosyl
extracellular
domain
subdivid
turn
sever
region
closest
amino
termin
part
start
flexibl
stalk
region
contain
possibl
nglycosyl
site
intermedi
region
highli
enrich
cystein
final
activ
centr
locat
toward
carboxyltermin
end
anoth
highli
conserv
region
human
broadli
distribut
varieti
cell
type
tissu
organ
lung
display
second
highest
activ
amongst
organ
especi
lung
parenchyma
contrari
bronchi
almost
express
found
apic
membran
epitheli
cell
capillari
endotheli
cell
fibroblast
seros
submucos
gland
human
bronchi
place
level
constitut
highli
correl
messeng
rna
mrna
content
http
tissu
howev
caus
strong
proinflammatori
upregul
airway
epitheli
cell
moreov
activ
protein
mrna
increas
allergen
exposur
lung
parenchyma
rat
model
allerg
airway
inflamm
suggest
lung
epithelium
could
import
asthma
pathogenesi
also
express
immun
system
detect
medullar
thymocyt
cell
area
spleen
lymph
node
peripher
blood
cell
lesser
extent
b
cell
nk
cell
monocytesmacrophag
granulocyt
densiti
cell
heavili
control
augment
upon
cell
activ
acquisit
memori
phenotyp
especi
cell
lineag
human
lymphocyt
display
variabl
basal
express
cell
depend
individu
mab
use
despit
rest
cell
contain
mrna
display
molecul
surfac
h
stimul
howev
certain
regul
mrna
level
detect
either
northern
blot
gene
array
upon
activ
addit
upregul
interferon
gamma
renal
epitheli
cell
bcll
modif
mrna
level
despit
describ
adjust
express
mrna
level
sever
evid
support
presenc
upstream
control
level
thu
strongli
regul
protein
level
sever
solubl
factor
exampl
cytokin
lesser
extent
enhanc
express
activ
cell
nk
cell
togeth
contrari
anoth
cytokin
effect
level
lymphocyt
regard
cytokin
promot
express
human
b
lymphocyt
activ
staphylococcu
aureu
cowan
cytokin
move
lack
effect
certain
downmodul
level
cell
high
concentr
unpublish
result
addit
vitro
exposur
regulatori
cell
treg
deriv
solubl
factor
like
transform
growth
factor
beta
adenosin
ado
lead
diminish
level
peripher
blood
treg
lymphocyt
display
bactivatedlik
eg
high
bmemori
banergicapoptosispronephenotyp
expect
express
activationmemori
marker
seem
case
rat
treg
effector
cell
teff
subset
peripher
cell
show
equival
express
contrast
human
treg
cell
high
high
display
lower
level
compar
teff
lymphocyt
like
explain
cytokin
favour
beffectorrespons
eg
caus
strong
upregul
bbulkt
h
cell
cultur
other
import
treg
homeostasi
eg
induc
slight
increas
level
also
give
clue
downmodul
upon
exposur
cell
express
amongst
teff
lymphocyt
also
variabl
cell
appear
display
highest
level
accord
follow
order
furthermor
two
subset
report
amongst
cell
base
express
subset
subpopul
high
phenotyp
find
like
indic
degre
phenotyp
divers
found
teff
cell
level
also
probabl
present
treg
reflect
presenc
function
differ
subset
mirror
correspond
teff
subset
differ
express
level
treg
teff
lymphocyt
could
depend
variat
mrna
level
like
happen
cell
classic
hodgkin
lymphoma
howev
worth
mention
apart
regul
set
mrna
molecul
intracellular
pool
protein
maintain
continu
translat
human
cell
regardless
phenotyp
mobil
toward
plasma
membran
releas
extracellular
space
therefor
could
number
addit
mechan
lead
phenotyp
human
treg
cell
found
extracellular
space
autocrin
paracrin
endocrin
effect
solubl
version
describ
mani
biolog
fluid
eg
serum
plasma
synovi
fluid
cerebrospin
fluid
differ
organ
bronchoalveolar
lavag
contain
enzymat
activ
rat
human
serum
plasma
least
activ
associ
heavili
glycosyl
isoform
whose
concentr
display
normal
distribut
high
biolog
variabl
seem
depend
preanalyt
variabl
like
age
gender
thu
serum
concentr
increas
year
children
valu
start
decreas
adult
slight
decreas
activ
serum
age
also
detect
studi
describ
correl
addit
differ
detect
regard
gender
studi
differ
author
find
higher
concentr
serumplasma
sampl
lower
express
cell
unpublish
result
male
sever
studi
found
posit
correl
activ
human
other
report
low
correl
instead
differ
explan
like
presenc
hypersialyl
isoform
altern
protein
activ
thu
plasma
sampl
contain
solubl
glycoprotein
name
dpptl
attractin
without
homolog
activ
although
activ
question
recent
attractin
accumul
plasma
membran
upon
cell
receptor
tcr
trigger
h
especi
high
teff
cell
unpublish
result
releas
plasma
h
curious
linkag
disequilibrium
studi
show
associ
asthma
region
includ
attractin
atrn
gene
upstream
gene
encod
secretasesheddas
asthma
suscept
gene
releas
could
accomplish
classic
nonclass
pathway
either
constitut
induc
mechan
classic
pathway
requir
vesicular
traffic
endoplasm
reticulumgolgi
toward
plasma
membran
intravesicular
protein
liber
extracellular
medium
membran
merg
exocytosi
transmembran
protein
appear
secretom
proteolysi
mediat
bsecretasesbsheddas
last
process
bshed
deliv
growth
factor
cytokin
receptor
probabl
molecul
like
addit
support
lack
posttranscript
splice
mrna
absenc
cytoplasm
transmembran
domain
result
puls
chase
transfect
experi
howev
detect
microvesicl
exosom
lymphocyt
http
wwwexocartaorg
therefor
constitut
induc
releas
vesicl
exosom
microvesicl
apoptot
bodi
medium
could
also
contribut
pool
circul
reflect
cell
subset
origin
bcell
lineag
fingerprint
cell
sourc
still
controversi
viscer
fat
least
obes
patient
overexpress
releas
badipokineinto
circul
data
support
presenc
posit
correl
fast
level
bodi
mass
index
bmi
solubl
may
also
origin
sourc
endotheli
cell
eg
lung
epitheli
cell
liver
bile
canaliculi
kidney
howev
immun
cell
also
like
sourc
thu
transplant
model
rat
determin
healthi
condit
bone
marrowderiv
cell
repres
signific
sourc
therefor
concentr
could
also
influenc
number
lymphocyt
mirror
predomin
phenotyp
circul
lymphocyt
patholog
situat
asthma
phenotyp
diseas
sever
level
cell
h
cell
play
central
role
adapt
immun
respons
inductionpersist
asthma
allergicatop
diseas
plastic
heterogen
lymphocyt
four
main
lineag
treg
cell
differ
role
exampl
cell
infiltr
airway
allerg
asthma
produc
set
cytokin
import
airway
remodel
leucocytosi
eosinophilia
macrophagemast
cell
activ
b
celldepend
ige
elev
way
h
lymphocyt
heterogen
also
number
asthma
phenotyp
like
reflect
h
cell
heterogen
high
low
phenotyp
share
differ
clinic
sign
earli
allerg
asthma
strong
familiar
background
mediat
cytokin
high
allergenspecif
ige
atopi
b
lessallerg
lateonset
asthma
high
character
eosinophil
inflamm
absenc
specif
ige
ie
nonatop
wors
respons
corticosteroid
c
neutrophil
asthma
low
phenotyp
refractori
corticosteroid
link
respons
sputum
neutrophilia
augment
level
obesityrel
asthma
low
phenotyp
predomin
obes
women
higher
level
tumor
necrosi
factor
alpha
leptin
low
number
eosinophil
tabl
therefor
altern
high
effector
h
subpopul
gain
import
asthma
particularli
diseas
becom
chronic
refractori
treatment
context
even
though
initi
describ
cell
protect
bhygien
hypothesi
consid
cell
could
favour
inflamm
airway
addit
interleukin
interleukin
forc
expiratori
volum
ab
antibodi
proinflammatori
high
cell
detect
biopsi
asthma
patient
cytokin
eg
involv
eosinophilianeutrophilia
higher
sever
acut
attack
hand
treg
cell
also
seem
play
relev
role
control
exagger
respons
asthma
develop
treg
cell
exert
suppressor
activ
use
solubl
eg
adenosin
membraneassoci
eg
molecul
number
gwa
asthma
identifi
gene
eg
link
suppressor
activ
thu
lower
higher
preval
differ
teff
subset
andor
distort
tefftreg
balanc
could
also
alter
phenotyp
sever
asthma
moreov
depend
asthma
phenotyp
sever
diseas
level
function
surfac
immun
cell
biofluid
could
rather
differ
factor
influenc
diseas
develop
therefor
time
ask
biolog
function
connect
asthma
function
speak
complex
molecul
harm
benefici
activ
relat
asthma
regard
first
one
tradit
link
amplif
tcrmediat
stimulatori
signal
cell
adhesionmigr
function
could
depend
product
certain
biomolecul
enzymat
activ
extracellular
associ
protein
adenosin
deaminas
ada
collagen
plasminogen
fibronectin
iii
fig
exampl
costimul
play
role
migrat
mesothelioma
cell
upregul
product
current
biomark
bt
higha
sthma
periostin
locat
could
also
import
harm
function
asthma
raft
resid
protein
improv
immunolog
synaps
format
antigenpres
cell
apc
cell
import
h
cell
proliferationdifferenti
empow
lymphocyt
proportion
help
b
cell
produc
immunoglobulin
like
ige
fig
raftdepend
costimulatori
function
could
mediat
protein
like
tyrosin
phosphatas
ptpase
essenti
tcr
signal
crosslink
antibodi
lymphocyt
drive
recruit
raft
interact
probabl
caus
dimer
dissoci
increas
ptpase
activ
signal
transduct
cascad
overlap
boost
tcr
pathway
fig
potenti
detriment
function
lung
person
asthma
seem
involv
activ
centr
necessarili
activ
thu
h
cell
recogn
induc
upregul
proinflammatori
molecul
apc
cell
interact
induc
coalesc
lipid
raft
recruit
activationnuclear
transloc
proinflammatori
brapid
actingtranscript
factor
nfkb
fig
therefor
high
phenotyp
teff
cell
may
favour
allergeninduc
inflamm
lung
phenotyp
treg
cell
may
contribut
keep
low
level
apc
trigger
anergyapoptosi
allergenspecif
cell
howev
find
costimulatori
role
need
clarif
either
partial
complet
genet
delet
use
inhibitor
impact
function
costimulatori
action
also
could
depend
interact
anoth
enzym
ada
ada
molecul
lymphocyt
cytosol
small
proport
associ
either
ado
receptor
ar
ar
ar
cell
membran
ectoada
bind
ada
take
place
human
murin
lymphocyt
interact
could
potenti
trigger
costimulatori
signal
favour
lymphocyt
prolifer
cytokin
chemokin
product
fig
turn
activ
complex
costimul
cytokin
increas
number
ectoada
molecul
format
triad
might
help
trap
chemokin
receptor
immunolog
synaps
make
lymphocyt
insensit
chemokin
stromal
cellderiv
factor
trigger
prolif
cytokinesecret
respons
fig
costimulatori
effect
could
also
come
capabl
enhanc
cellmedi
reaction
recal
antigen
eg
tetanu
toxoid
suboptim
amount
polyclon
stimuli
pha
contrari
initi
result
recent
data
point
proinflammatori
effect
depend
adabind
activ
like
trigger
upon
interact
protein
like
insulinlik
growth
factor
receptor
apc
proteaseactiv
receptor
smooth
muscl
cell
promot
upregul
apc
gener
reactiv
oxygen
speci
ro
tolllik
receptor
fig
major
member
prolyl
oligopeptidas
famili
cleav
xprolin
xalanin
dipeptid
nterminu
differ
polypeptid
even
though
amino
acid
accept
lower
effici
pro
ala
hyp
ser
gli
val
leu
apart
primari
sequenc
structur
size
substrat
ioniz
optimum
ph
significantli
influenc
catalyt
effici
peptid
contain
xprolin
xalanin
nterminu
easi
process
proteas
mean
key
biolog
role
inde
activ
link
activ
lymphocyt
respons
extracellular
stimuli
exampl
jurkat
cell
transfect
display
greater
activ
express
molecul
activ
also
necessari
molecul
boost
tetanu
toxoiddepend
prolifer
inhibitor
yield
similar
result
vitro
suppress
cell
prolifer
secret
proinflammatori
cytokin
enhanc
releas
vivo
use
inhibitor
murin
model
human
diseas
like
rheumatoid
arthriti
multipl
sclerosi
asthma
aerosol
simultan
allergen
also
describ
proinflammatori
role
moreov
inhibitor
also
support
posit
role
inflammasom
format
howev
enzym
activ
requir
absolut
term
costimulatori
function
sinc
biolog
activ
retain
delet
part
hydrolas
domain
fig
apart
costimulatori
asthmadetriment
role
also
evid
exhibit
asthmaprevent
activ
protect
function
link
indirect
direct
control
differ
solubl
mediat
like
ado
bradykinin
neuropeptid
involv
bronchoconstrict
inflamm
chemoattract
airway
remodel
asthma
patient
instanc
nucleosid
ado
substrat
ada
enzym
catalys
irrevers
deamin
inosin
alreadi
mention
ada
found
anchor
fig
mani
cell
two
frequent
regard
proinflammatori
ar
ar
ar
also
interact
enzym
seem
import
effici
liganddepend
signal
ar
novel
target
treatment
human
asthma
antagonist
agonist
enter
clinic
phase
total
clear
efficaci
inde
elev
express
asthmafavour
adainteract
receptor
ar
ar
bronchial
tissu
probabl
reduc
amount
asthmaprotect
ar
addit
augment
ado
concentr
extracellular
compart
asthma
nucleosid
play
detriment
role
fig
function
membran
solubl
asthma
figur
summar
posit
ie
favour
asthma
develop
exacerb
neg
ie
prevent
asthma
develop
exacerb
function
diseas
diseas
caus
bronchoconstrict
airway
inflamm
eg
mast
cell
degranul
airway
accumul
eosinophil
airway
remodel
edema
mucu
product
harm
effect
also
depend
specif
engag
type
purinerg
receptor
particular
cell
express
ar
airway
eg
apc
lymphocyt
eosinophil
neutrophil
endotheli
mast
epitheli
endotheli
smooth
muscl
cell
role
ado
asthma
affect
bind
affin
receptor
densiti
local
level
nucleosid
influenc
delic
balanc
differ
mechan
involv
eg
extracellularintracellular
ado
metabol
amongst
mechan
ado
catabol
mediat
ada
molecul
anchor
major
regul
pathway
influenc
local
concentr
biolog
effect
ado
respect
relev
cytokin
allerg
asthma
reduc
ada
activ
lung
ectoada
level
h
lymphocyt
find
suggest
low
level
subset
high
allergicatop
asthma
could
favour
local
accumul
ado
activ
ar
particip
proinflammatori
ar
requir
ado
concentr
physiolog
level
eg
lowaffin
ar
order
neutral
offsign
provid
engag
highaffin
asthmaprotect
ar
therefor
like
artarget
therapi
effect
high
asthma
low
sever
asthma
wherein
high
cell
frequent
moreov
addit
studi
need
clarifi
could
exactli
role
treg
cell
asthma
lymphocyt
subset
low
phenotyp
favour
high
product
ado
hand
involv
janu
kinas
dephosphoryl
therefor
associ
could
neg
role
import
restrain
signal
transduct
cytokin
receptor
fig
sens
low
ptpase
activ
human
cell
make
suscept
small
amount
mention
import
cytokin
allerg
asthma
memoryeffector
high
cell
secret
solubl
factor
upon
activ
less
sensit
effect
inde
high
level
memoryeffector
h
lymphocyt
might
act
bbrakefor
prolif
respons
cytokin
exampl
unpublish
result
protect
function
asthma
could
also
link
activ
fig
substrat
fall
outsid
scope
immun
system
review
like
incretin
glucosedepend
insulinotrop
peptid
gip
glucagonlik
glucagonlik
glucagon
pituitari
adenyl
cyclaseactiv
polypeptid
pacap
gastrinreleas
peptid
grp
peptid
yy
vasoact
peptid
bradykinin
vasoact
intestin
peptid
vip
natriuret
peptid
btype
natriuret
peptid
bnp
neuropeptid
neuropeptid
npi
betacasomorphin
endomorphin
substanc
p
tabl
howev
other
import
immunomodulatori
role
cytokin
eg
gcsf
gmcsf
chemokin
eg
enzymat
activ
downmodul
biolog
function
chemokin
cytokin
tabl
consist
observ
found
inhibitor
enhanc
vivo
immun
respons
depend
dose
applic
rout
time
predomin
teff
subset
could
explain
presenc
offtarget
effect
well
howev
anim
model
rheumatoid
arthriti
multipl
sclerosi
inflammatori
bowel
diseas
ko
mice
support
immunosuppress
role
activ
immunosuppress
function
also
observ
strong
vitro
prolif
respons
immun
cell
moreov
even
regard
tumour
suppressor
gene
melanoma
neuroblastoma
reason
focu
part
review
substrat
direct
connect
immun
system
like
chemokin
even
though
cytokin
like
contain
appropri
ntermin
sequenc
molecular
weight
preclud
ntermin
clip
except
like
granulocyt
colonystimul
factor
gcsf
granulocytemacrophag
colonystimul
factor
gmcsf
erythropoietin
epo
contrast
process
chemokin
kda
like
rant
regul
activ
normal
cell
express
secret
one
interest
aspect
biolog
moreov
function
mostli
depend
level
influenc
cell
subset
diseas
seen
chemokin
proinflammatori
cytokin
role
leukocyt
activ
migrat
classifi
accord
posit
two
ntermin
cystein
residu
cc
cxc
c
also
divid
function
cell
attract
receptor
recogn
tabl
show
major
branch
effector
regulatori
cell
express
characterist
total
select
chemokin
receptor
exampl
lymphocyt
leukocyt
import
asthma
basophil
mast
cell
eosinophil
express
human
interact
substrat
actual
specif
cell
regard
cell
seem
display
slight
overexpress
compar
lymphocyt
author
describ
mere
traffick
marker
ligat
particip
recruit
basophil
eosinophil
mast
cell
tabl
eotaxin
import
chemokin
allerg
asthma
produc
endotheli
cell
monocyt
respons
respect
chemokin
recogn
eosinophil
basophil
mast
cell
lesser
extent
put
marker
see
later
eotaxin
chemoattract
eosinophil
facilit
mobil
bone
marrow
truncat
eotaxin
character
intermediatelow
effici
k
cat
k
mdc
itac
mig
eotaxin
rant
despit
ntermin
clip
result
isoform
reduc
chemotact
activ
caus
desensit
inde
administr
eotaxin
rat
lead
mobil
eosinophil
effect
enhanc
anim
inhibitor
addit
mice
challeng
ovalbumin
ova
show
higher
level
ligand
eotaxin
rant
stronger
eosinophil
infiltr
lung
anoth
ligand
tabl
chemokin
process
plasmin
urokinas
plasminogen
activ
upa
yield
isoform
bind
also
effici
attract
eosinophil
monocyt
cell
process
also
dampen
therefor
phenotyp
eosinophil
cell
seem
favour
inflammatori
respons
high
asthma
found
monocyt
bt
preferenti
cell
promot
recruit
cell
lung
allerg
airway
diseas
recogn
macrophag
migrat
inhibitori
fact
r
f
n
r
l
c
e
l
l
e
r
v
e
f
c
r
tabl
last
one
small
chemokin
synthes
endotheli
cell
fibroblast
induc
tb
cell
activ
regul
traffic
lymphocyt
monocyt
dendrit
cell
toward
inflam
epithelia
amongst
sever
isoform
least
two
effici
process
vitro
vivo
isoform
unabl
activ
display
antagonist
activ
moreov
similar
express
kinet
upon
activ
interact
lymphocyt
bind
initi
complex
endocytosi
process
disrupt
ntermin
clip
find
could
explain
howev
preferenti
express
low
cell
eg
h
cytokin
induc
downmodul
lead
augment
express
potenti
f
c
x
c
r
x
h
c
low
phenotyp
also
facilit
vigor
respons
recruit
cell
eosinophil
mous
model
lung
allerg
inflamm
hand
also
posit
correl
vitro
invas
capac
cell
line
respons
posit
effect
mediat
tyrosin
phosphatas
enhanc
cell
migrat
respons
present
monocyt
dendrit
cell
nk
cell
h
cell
treg
recogn
tabl
last
chemokin
produc
macrophag
dendrit
cell
nk
cell
bt
lymphocyt
tarc
mdc
express
epitheli
cell
airway
level
upregul
allergen
challeng
cytokin
eg
lp
stimul
secret
mdc
wherea
cytokin
eg
inhibit
mdc
product
moreov
mdc
gener
amplifi
h
r
e
p
n
e
n
r
e
c
r
u
h
l
p
h
c
e
import
diseas
cytokin
profil
eg
asthma
equival
model
mice
model
domin
role
later
chronic
stage
diseas
compar
furthermor
process
mdc
halflif
min
effici
gener
mdc
subsequ
mdc
last
isoform
preserv
attract
power
monocyt
display
reduc
chemotact
activ
lymphocyt
dendrit
cell
two
subset
import
asthma
treg
cell
cell
cell
high
cell
phenotyp
subset
appar
facilit
recruit
inflammatori
site
asthma
patient
present
high
diseas
two
type
obesityassoci
neutrophil
asthma
link
low
ie
profil
high
cell
subset
display
low
effectormemori
phenotyp
produc
cytokin
cell
lymphocyt
essenti
product
igm
igg
iga
ige
b
cell
orchestr
respons
intracellular
microb
ligand
chemokin
substrat
tabl
exampl
produc
endotheli
epitheli
cell
platelet
macrophag
eosinophil
cell
rant
activ
preferenti
therebi
attract
monocyt
eosinophil
cell
inflammatori
site
chemokin
cleav
low
effici
halflif
min
lead
rant
chemokin
lose
capac
bind
monocyt
eosinophil
cell
express
low
effectormemori
cell
high
mean
rant
favour
attract
toward
inflammatori
site
anoth
chemokin
substrat
bind
macrophag
inflammatori
encod
two
differ
loci
chemokin
agonist
bind
high
affin
regul
trafficactiv
macrophagesmonocyt
nk
cell
eosinophil
basophil
immatur
dendrit
cell
lymphocyt
strikingli
ineffici
halflif
h
clip
gener
enhanc
chemotact
activ
cell
monocytesneutrophil
tabl
fact
togeth
low
phenotyp
eosinophil
reduc
affin
prove
posttransl
modif
tend
favour
respons
overrepres
cell
recogn
chemokin
secret
endotheli
cell
hepatocyt
fibroblast
keratinocyt
leucocyt
respons
infect
sever
diseas
includ
asthma
chemokin
import
bring
cell
epitheli
barrier
moreov
ntermin
process
intermediatehigh
effici
tabl
becom
less
activ
chemoattract
addit
modif
also
make
antagonist
induc
receptor
desensit
part
neg
feedback
mechan
import
downmodul
inflamm
lymphocyt
play
major
role
tissu
inflamm
essenti
activ
macrophag
recruit
neutrophil
drive
defens
activ
extracellular
bacteria
fungi
human
cell
associ
express
skinhom
addressin
eg
also
share
treg
cell
cell
howev
cell
rare
site
inflamm
mayb
due
homeostat
mechan
avoid
expans
high
plastic
shift
cell
heterogen
express
proinflammatori
high
phenotyp
cell
small
subset
immunosuppress
low
heterogen
also
detect
cell
lineag
produc
express
cla
play
antiinflammatori
tissueprotect
role
asthma
curious
cell
wherea
cell
constitut
either
lymphocyt
summari
take
consider
express
gradient
major
h
subset
reg
small
proport
chemokin
affect
reg
cell
process
compar
recruit
cell
clip
produc
drop
biolog
function
evid
form
part
homeostat
mechan
downmodul
airway
inflamm
mediat
especi
cell
eg
obesitylink
asthma
despit
report
evid
role
diseas
involv
peptidasedepend
peptidaseindepend
function
pathophysiolog
asthma
yet
fulli
understood
section
summar
result
obtain
anim
model
human
system
rat
model
use
inhal
allergen
ova
use
evalu
role
bronchial
asthma
thu
sever
airway
inflamm
decreas
endogen
level
strain
becom
lower
like
due
costimulatori
role
one
model
extens
use
strain
challeng
rat
ova
gener
bronchoconstrict
higher
express
lymphocyt
epitheli
cell
lung
parenchyma
enhanc
level
bronchi
dosedepend
recruit
lung
dendrit
cell
eosinophil
cell
specif
ova
caus
increas
recruit
cell
bronchi
lung
parenchyma
enhanc
activ
bronchoalveolar
lavag
fluid
balf
last
find
like
relat
augment
presenc
cell
bronchi
interestingli
substrain
activesit
mutat
gene
caus
protein
retentiondegrad
endoplasm
reticulum
lower
level
substrain
also
display
earli
bronchoconstrict
respons
ova
challeng
late
inflammatori
respons
milder
regard
ovaspecif
serum
ige
eosinophilia
recruit
cell
bronchi
balf
contrast
entranc
cell
bronchoalveolar
lymphoid
tissu
balt
enhanc
matter
phenotyp
transfer
cell
bronchi
compart
cell
recruit
airway
ovachalleng
rat
either
h
cell
low
phenotyp
downmodul
peribronchi
infiltr
thu
potenti
higher
respons
cell
could
allow
recruit
bronchi
high
environ
wildtyp
rat
concomit
downmodul
happen
skin
home
cell
contrast
teff
cell
rat
would
attract
bronchi
result
either
anomalousaberr
respons
reduc
chemokin
gradient
result
milder
asthmalik
diseas
howev
despit
augment
bronchi
asthmat
patient
ova
challeng
increas
number
transcript
larg
airway
rat
curious
amount
increas
balt
rat
like
support
comment
higher
recruit
cell
lymphoid
compart
ova
challeng
rat
display
parallel
increas
influx
treg
lung
concomit
rais
product
explain
diminish
inflamm
howev
may
happen
way
human
treg
cell
display
phenotyp
contrast
rat
moreov
difficult
concili
milder
asthmaticlik
inflamm
ovachalleng
rat
either
lower
truncat
rate
chemokin
eg
eotaxin
vivo
enhanc
eotaxinmedi
recruit
eosinophil
caus
inhibitor
perhap
differ
genet
background
administr
rout
might
play
signific
role
exampl
oral
administr
inhibitor
seem
enhanc
allerg
inflamm
airway
wherea
topic
inhibit
aerosol
rather
protect
effect
line
observ
rat
moreov
dual
defici
enzymat
extraenzymat
activ
murin
asthma
model
may
gener
result
differ
observ
effect
inhibitor
inhibit
enzymat
function
ko
mice
display
healthi
phenotyp
increas
glucos
clearanc
resist
obes
small
chang
percentag
nk
nkt
cell
addit
vitro
pokewe
mitogen
pwm
activ
splenocyt
mice
show
decreas
product
ige
significantli
reduc
sera
anim
upon
pwm
treatment
clear
contrast
yan
et
al
report
unchang
ige
concentr
enhanc
eosinophilia
cytokin
balf
ovainduc
anim
well
higher
mrna
protein
level
substrat
eotaxin
rant
chemokin
receptor
partial
contradictori
result
probabl
depend
type
administr
rout
strength
polyclon
stimulu
pwm
vs
ova
also
point
induc
target
cell
typespecif
ko
model
could
necessari
truli
dissect
role
asthma
line
small
differ
level
observ
cell
marker
help
differenti
driven
respons
patient
atop
asthma
howev
augment
level
actual
detect
total
lymphocyt
cell
inkt
lymphocyt
monocyt
b
cell
adult
allerg
asthma
reflect
exist
activ
statu
last
work
also
publish
elev
plasma
patient
associ
eosinophil
count
ige
concentr
addit
group
report
lower
product
chemokin
mig
higher
presenc
chemokin
rant
mdc
receptor
case
attribut
respons
predomin
clear
contrast
matsuno
et
al
found
invers
correl
inflamm
level
chronic
eosinophil
pneumonia
diseas
frequent
preced
accompani
asthma
recent
differ
found
serum
level
children
asthma
associ
variabl
either
asthma
atopi
eg
skin
prick
test
ige
eosinophil
cation
protein
analysi
studi
need
expand
differ
asthmat
phenotyp
endotyp
level
severitychron
obviou
addit
also
clear
variabl
sampl
size
lymphocyt
count
age
sex
also
taken
account
especi
know
influenc
sex
membranebound
unpublish
result
level
b
augment
preval
asthma
boy
earli
age
higher
preval
asthma
women
puberti
especi
case
certain
low
phenotyp
exampl
appar
increas
blood
atop
dermat
like
diseas
adult
asthma
patient
last
studi
result
might
partial
explain
higher
proport
male
group
patient
contrast
reme
show
alter
level
asthmat
children
took
consider
certain
preanalyt
variabl
gender
age
therefor
studi
need
reveal
potenti
correl
sever
phenotyp
asthmat
patholog
high
bodi
mass
index
factor
posit
associ
asthma
develop
sever
associ
asthma
obes
appear
stronger
women
men
role
noninflammatori
subclinicalsystem
chronic
inflammatori
pathway
includ
releas
proinflammatori
eg
leptin
antiinflammatori
eg
adiponectin
adipokin
regul
surviv
eosinophil
recruit
lung
mention
viscer
fat
obes
patient
releas
circul
alreadi
highlight
throughout
review
proinflammatori
antiinflammatori
effect
depend
process
substrat
incretin
chemokinessubst
p
respect
obes
person
risk
number
comorbid
like
type
diabet
mellitu
diseas
character
impair
product
incretin
subsequ
hyperglycaemia
incretin
gip
wellknown
substrat
lose
function
process
inhibit
enzymat
activ
avoid
degrad
hormon
enhanc
incretin
effect
improv
insulin
secret
glucos
uptak
lower
glycosyl
haemoglobin
level
achiev
goal
new
group
antihyperglycaem
drug
inhibitor
gliptin
come
market
sitagliptin
merck
sharp
dohm
ltd
vildagliptin
novarti
europharm
ltd
approv
european
medicin
agencyema
first
outpost
tabl
current
sever
oral
administ
inhibitor
approv
agenc
like
food
drug
administr
fda
ema
use
satisfactori
result
secondor
thirdlin
medic
combin
oral
antidiabet
drug
commerci
avail
gliptin
includ
abovement
sitagliptin
also
saxagliptin
linagliptin
alogliptin
vildagliptin
tabl
howev
controversi
debat
secondari
effect
comorbid
eg
cardiovascular
outcom
renal
impair
acut
pancreat
longterm
treatment
long
halflif
inhibitor
may
concern
result
sever
issu
relat
great
number
substrat
link
immun
system
thu
savor
saxagliptin
trial
detect
significantli
increas
rate
hospit
due
heart
failur
recent
studi
base
faer
usfda
advers
event
report
system
also
consist
find
clear
contrast
teco
trial
sitagliptin
find
increas
risk
heart
failur
accord
scope
review
revers
inhibitor
seem
increas
frequenc
risk
factor
asthma
developmentexacerb
like
atop
sensit
rhiniti
rhinoviru
infect
patient
thu
rapid
review
clinic
data
publish
ema
web
page
http
wwwemaeuropaeu
support
increas
risk
nonseri
upper
respiratori
tract
infect
eg
viral
nasopharyng
rhiniti
sinus
tabl
would
line
costimulatori
role
willemen
coauthor
sustain
increas
risk
infect
inhibitor
case
compar
magnitud
effect
seen
biolog
agent
like
tumour
necrosi
factor
inhibitor
howev
effect
underestim
must
ad
immun
impair
caus
increas
overal
asthma
developmentexacerb
risk
patient
advers
drug
reaction
adr
report
associ
gliptin
associ
inhibitori
role
would
interstiti
lung
diseas
hypersensit
reaction
includ
anaphylact
respons
bronchial
hyperreact
skin
subcutan
tissu
disord
pruritu
angioedema
rash
urticaria
cutan
vascul
sever
rare
skin
condit
tabl
exampl
bullou
pemphigoid
autoimmun
subepiderm
diseas
overproduct
eotaxin
eosinophilia
affect
skin
mucosa
therefor
associ
gliptin
bullou
pemphigoid
tune
vivo
studi
rat
show
limit
eotaxinmedi
recruit
eosinophil
find
oral
administr
inhibitor
promot
allerg
inflamm
airway
mean
could
part
homeostat
mechan
downmodul
airway
inflamm
mediat
especi
cell
import
low
asthma
phenotyp
obesityrel
asthma
nevertheless
note
besid
chemokin
substrat
implic
obes
asthma
like
substanc
p
inhal
substanc
p
bradykinin
enhanc
airway
respons
bronchoconstrict
agent
guinea
pig
substanc
p
also
favour
allergen
sensit
bronchial
inflamm
observ
mous
model
dietinduc
obes
sensit
challeng
ova
treat
antagonist
substanc
p
receptor
therefor
expand
halflif
substanc
p
caus
treatment
inhibitor
patient
could
increas
certain
obesityrel
comorbid
asthma
way
administr
sitagliptin
gener
temporari
decreas
percentag
peripher
blood
treg
also
could
favour
asthma
preval
patient
clear
contrast
therapi
antiinflammatori
effect
chronic
inflammatori
diseas
includ
asthma
exampl
vitro
studi
describ
inhibitor
induc
decreas
inflammasom
tolllik
receptor
signal
macrophag
via
receptor
therefor
studi
need
clarifi
whether
gliptin
overal
posit
neg
role
patient
obesityrel
asthma
relev
molecul
asthma
sever
reason
first
one
potenti
util
togeth
periostin
test
efficaci
treatment
monoclon
antibodi
eg
tralokinumab
patient
sever
uncontrol
asthma
secondli
multifunction
natur
costimulatori
inhibitori
role
immun
system
apart
high
variabl
level
subset
lymphocyt
central
asthma
cell
differ
author
highlight
inhibitori
function
molecul
rel
signal
mediat
cytokin
chemokin
hand
chemokin
import
cell
earlyonset
allerg
lateonset
eosinophil
asthma
includ
chemotact
factor
whose
biolog
activ
reduc
lowintermedi
upper
respiratori
infect
common
nasopharyng
common
hypersensit
reaction
known
b
pruritu
common
rash
common
exfoli
skin
condit
includ
stevensjohnson
syndrom
erythema
multiform
angioedema
urticaria
known
b
absolut
frequenc
adr
common
common
uncommon
rare
rare
known
ie
estim
b
advers
drug
reaction
adr
identifi
base
postmarket
surveil
eotaxin
high
mdc
effici
wherea
import
chemokin
itac
mig
high
cell
mdc
two
teff
subset
relev
obesityrel
asthma
lateonset
neutrophil
asthma
sever
asthma
inactiv
intermediatehigh
effect
therefor
could
act
bbiolog
brakebi
reduc
attract
teff
cell
site
inflamm
eg
bronchi
mean
inhibitor
use
patient
could
lead
higher
persist
unprocess
substanc
p
chemokin
exacerb
high
especi
low
asthma
conclus
necessari
previous
take
consider
mani
exist
question
regard
biolog
function
enzym
therapeut
target
molecul
inhibitor
could
enhanc
frequenc
hospit
admiss
amongst
peopl
certain
asthma
phenotyp
